US 12,257,313 B2
Preparation of therapeutic exosomes using membrane proteins
Kevin P. Dooley, Boston, MA (US); Rane A. Harrison, Belmont, MA (US); Russell E. McConnell, Brighton, MA (US); Ke Xu, Sudbury, MA (US); Damian J. Houde, Plymouth, MA (US); Nikki Ross, Cambridge, MA (US); Sonya Haupt, Cambridge, MA (US); John D. Kulman, Belmont, MA (US); and Douglas E. Williams, Boston, MA (US)
Assigned to LONZA SALES AG, Basel (CH)
Filed by LONZA SALES AG, Basel (CH)
Filed on Oct. 26, 2022, as Appl. No. 18/050,005.
Application 18/050,005 is a division of application No. 16/722,884, filed on Dec. 20, 2019, granted, now 11,679,164.
Application 16/722,884 is a continuation of application No. 16/231,012, filed on Dec. 21, 2018, granted, now 10,561,740, issued on Feb. 18, 2020.
Application 16/231,012 is a continuation of application No. 16/112,547, filed on Aug. 24, 2018, granted, now 10,195,290, issued on Feb. 5, 2019.
Claims priority of provisional application 62/656,956, filed on Apr. 12, 2018.
Claims priority of provisional application 62/550,543, filed on Aug. 25, 2017.
Prior Publication US 2024/0009322 A1, Jan. 11, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/69 (2017.01); C07K 14/705 (2006.01); C07K 14/71 (2006.01); C07K 14/755 (2006.01); C07K 16/28 (2006.01); A61K 38/00 (2006.01)
CPC A61K 47/6917 (2017.08) [C07K 14/705 (2013.01); C07K 14/70503 (2013.01); C07K 14/70596 (2013.01); C07K 14/71 (2013.01); C07K 14/755 (2013.01); C07K 16/2803 (2013.01); C07K 16/2851 (2013.01); A61K 38/00 (2013.01); C07K 2317/55 (2013.01); C07K 2317/622 (2013.01); C07K 2319/00 (2013.01); C07K 2319/30 (2013.01); C07K 2319/43 (2013.01); C07K 2319/60 (2013.01)] 19 Claims
 
1. A pharmaceutical composition comprising:
a. an exosome comprising a target protein, wherein at least a part of the target protein is expressed from an exogenous sequence, and the target protein comprises Prostaglandin F2 Receptor Negative Regulator (PTGFRN) or a fragment thereof and:
b. an excipient.